Lake Bleu Capital
VC Fund
Hong Kong, Hong Kong
Lake Bleu Capital is a Hong Kong-based investment platform that specializes in healthcare.
- Total investments:
- 36
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Lake Bleu Capital invests in
Stages Lake Bleu Capital invests in
Countries Lake Bleu Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bin Li
|
|||
Investment Focus
Industry
- Health Care 23 (64%)
- Biotechnology 19 (53%)
- Medical 11 (31%)
- Pharmaceutical 8 (22%)
- Biopharma 4 (11%)
Stage
- Series B 9 (25%)
- Series C 9 (25%)
- Series A 5 (14%)
- Series D 4 (11%)
- Series E 3 (8%)
Country
- China 27 (75%)
- United States 6 (17%)
- Hong Kong 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bin Li
Founding Partner and CEO
|
Founding Partner and CEO | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Sanegene Bio
|
Sanegene Bio is currently operating in stealth mode. | $110M / Series B / Dec 08, 2025 | |
|
|
Expedition Therapeutics operates as an unincorporated association. | Seed / Mar 20, 2025 | |
|
|
Mol Breeding is a biotech firm that focuses on animal and plants molecular breeding technology R&D and services. | $34.5M / Series B / Jul 30, 2024 | |
|
|
Zhejiang Boner Medical Investment Management Co., Ltd. is a well-known professional hospital investment operator in the Yangtze River Delta, featuring major orthopaedics and rehabilitation. | $109.8M / Series E / Nov 09, 2023 | |
|
|
HC Scientific is a high-tech enterprise integrating research, development, production and sales of a new biomedical system | $41.2M / Series B / Aug 28, 2023 | |
|
|
Center Medical is a cardiovascular medical services chain focused on developing a professional cardiovascular chain clinic brand. | Series A / Jul 17, 2023 | |
|
|
CoJourney is a CDMO platform for gene therapy that combines plasmid, viral vector, and mRNA generation, analysis, and detection. | $30M / Series A / Jun 27, 2023 | |
|
|
Raynovent is a science-driven innovative biotech company. | $53.6M / Series C / Dec 30, 2022 | |
|
|
BANGBANG ROBOT manufactures and sells movable assistant robot for the disabled people. | $14.9M / Series B / Jun 29, 2022 | |
|
|
Shenji Bio is a developer of POCT diagnostic products and tumor molecular diagnostic products. | $47.1M / Series A / Apr 11, 2022 | |
| See all 36 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Lake Bleu Capital invest in?
Lake Bleu Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 36 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Lake Bleu Capital?
Public channels for Lake Bleu Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lake Bleu Capital?
The team at Lake Bleu Capital includes Bin Li (Founding Partner and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!